Innovent Biologics has achieved a pioneering regulatory milestone with the approval of mazdutide in China for obesity treatment. It becomes the first dual GLP-1/glucagon receptor agonist to gain approval for this indication globally. This novel mechanism offers a differentiated therapeutic approach in the obesity landscape, addressing a significant unmet medical need in a rapidly expanding patient population. The approval underscores Innovent’s growing footprint in the metabolic disease market and presents potential implications for global obesity therapeutics.